BioMarin Pharmaceutical Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BMRN Nasdaq 2836 www.biomarin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations - Aug 6th, 2026 2:25 pm
BioMarin Reports Second Quarter 2026 Financial and Operating Results - Aug 6th, 2026 2:03 pm
1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down - Aug 3rd, 2026 3:17 pm
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET - Jul 30th, 2026 7:00 am
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? - Jul 28th, 2026 8:00 am
BioMarin and n-Lorem partner on early research for ReNU syndrome therapy - Jul 28th, 2026 4:30 am
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for - Jul 27th, 2026 8:00 am
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome - Jul 27th, 2026 7:05 am
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Jul 17th, 2026 9:45 am
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside - Jul 16th, 2026 7:06 am
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo - Jul 14th, 2026 8:42 am
BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation - Jul 13th, 2026 4:16 pm
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid - Jul 13th, 2026 11:10 am
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia - Jul 13th, 2026 7:05 am
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? - Jul 10th, 2026 6:14 am
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside - Jul 8th, 2026 6:48 am
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore - Jun 29th, 2026 5:46 am
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off - Jun 26th, 2026 8:48 am
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest - Jun 25th, 2026 9:37 am
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? - Jun 25th, 2026 6:45 am